Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 75.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,761,739 shares of the company’s stock after purchasing an additional 1,611,698 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.20% of Amneal Pharmaceuticals worth $47,398,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in Amneal Pharmaceuticals during the third quarter valued at approximately $31,000. Focus Partners Wealth bought a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $42,000. Advisory Services Network LLC acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $50,000. Finally, Bellevue Group AG bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $79,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Truist Financial raised their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Barclays assumed coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $14.20.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $12.07 on Wednesday. Amneal Pharmaceuticals, Inc. has a 12 month low of $6.68 and a 12 month high of $15.42. The stock has a fifty day moving average price of $13.66 and a 200 day moving average price of $12.14. The company has a market cap of $3.80 billion, a P/E ratio of 52.48 and a beta of 1.35.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.